Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.72 |
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | UNG | P13051 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.54 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3130174 | 0.89 | UNG (0.71) | AKR1C3KMOKDM4EUNGNPC1 | |
| SCHEMBL1042631 | 0.88 | AKR1C3 (0.92) | AKR1C3KMOKDM4ENPC1POLB | |
| SCHEMBL30266789 | 0.88 | AKR1C3 (0.92) | AKR1C3KMOKDM4ENPC1POLB | |
| SCHEMBL29546656 | 0.86 | AKR1C3 (0.96) | AKR1C3KMOKDM4ENPC1POLB | |
| SCHEMBL4320685 | 0.86 | AKR1C3 (0.96) | AKR1C3KMOKDM4ENPC1POLB | |
| SCHEMBL28701196 | 0.86 | AKR1C3 (0.96) | AKR1C3KMOKDM4ENPC1POLB | |
| SCHEMBL28313588 | 0.86 | PARP10 (0.73) | AKR1C3KDM4EPARP10PARP3TNKS | |
| SCHEMBL70012 | 0.84 | AKR1C3 (0.85) | AKR1C3KMOKDM4ENPC1POLB | |
| SCHEMBL16429240 | 0.84 | AKR1C3 (0.85) | AKR1C3KMOKDM4ENPC1POLB | |
| SCHEMBL30307447 | 0.84 | AKR1C3 (0.85) | AKR1C3KMOKDM4ENPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314004-B1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12162905-B2 | Carboxy substituted glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-11618767-B2 | Carboxy substituted glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-09-29 | — | — | US | disclosed |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-09-29 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2188254-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | AKR1C3 51/4885KMO 798/4885KDM4E 2384/4885 |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | AKR1C3 188/4885KMO 752/4885KDM4E 4017/4885 |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | AKR1C3 51/4885KMO 798/4885KDM4E 2384/4885 |
| US-11618767-B2 | Carboxy substituted glucocorticoid receptor agonists | NR3C1, MC2R, NR3C2 | AKR1C3 51/4885KMO 798/4885KDM4E 2384/4885 |
| US-12162905-B2 | Carboxy substituted glucocorticoid receptor agonists | NR3C1, MC2R, NR3C2 | AKR1C3 51/4885KMO 798/4885KDM4E 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.